We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+29.4%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.45B
AUM Growth
+$253M
Cap. Flow
-$255M
Cap. Flow %
-7.4%
Top 10 Hldgs %
43.88%
Holding
127
New
16
Increased
25
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$62.7M
2
BLU
BELLUS Health Inc.
BLU
+$50.1M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$48.2M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$42.4M
5
EW icon
Edwards Lifesciences
EW
+$31.8M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$38.2M
2
LLY icon
Eli Lilly
LLY
+$32.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.2M
5
CHRS icon
Coherus Oncology
CHRS
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 98.21%
2 Miscellaneous 1.6%
3 Financials 0.19%
4 Consumer Staples 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
76
Revolution Medicines
RVMD
$43.9B
$6.12M 0.18%
+310,500
New +$6.82M
ACRS icon
77
Aclaris Therapeutics
ACRS
$814M
$5.37M 0.16%
341,239
– –
NTRA icon
78
Natera
NTRA
$50.6B
$5.26M 0.15%
+120,000
New +$5.71M
TCDA
79
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
$5.24M 0.15%
+500,000
New +$5.47M
NARI
80
DELISTED
Inari Medical, Inc. Common Stock
NARI
$5.08M 0.15%
+70,000
New +$5.21M
NVNO
81
enVVeno Medical
NVNO
$6.48M
$4.91M 0.14%
22,332
– –
WGS icon
82
GeneDx Holdings
WGS
$2.82B
$4.39M 0.13%
151,515
– –
SLGC
83
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.35M 0.13%
1,500,000
– –
TYRA icon
84
Tyra Biosciences
TYRA
$1.52B
$4.35M 0.13%
494,403
– –
CTIC
85
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4.28M 0.12%
+735,165
New +$4.58M
ATNX
86
DELISTED
Athenex, Inc. Common Stock
ATNX
$4.18M 0.12%
776,623
+100,000
+15% +$1.03M
ABOS icon
87
Acumen Pharmaceuticals
ABOS
$209M
$4.01M 0.12%
400,000
-108,532
-21% -$623K
PNT
88
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$3.87M 0.11%
500,000
-573,995
-53% -$4.87M
HCAT icon
89
Health Catalyst
HCAT
$129M
$3.78M 0.11%
389,962
-75,200
-16% -$996K
NBTX
90
Nanobiotix
NBTX
$1.79B
$3.75M 0.11%
1,059,800
– –
YMAB
91
DELISTED
Y-mAbs Therapeutics
YMAB
$3.06M 0.09%
212,018
– –
PYXS icon
92
Pyxis Oncology
PYXS
$278M
$3.01M 0.09%
1,528,812
– –
ABSI icon
93
Absci
ABSI
$1.36B
$2.8M 0.08%
894,346
– –
PSTX
94
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.65M 0.08%
+750,000
New +$2.48M
CLOV icon
95
Clover Health Investments
CLOV
$2.48B
$2.55M 0.07%
1,500,000
– –
RETA
96
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.51M 0.07%
+100,000
New +$2.77M
QTNT
97
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.43M 0.07%
405,020
– –
SNCE
98
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.42M 0.07%
75,000
– –
FULC icon
99
Fulcrum Therapeutics
FULC
$288M
$2.38M 0.07%
294,118
– –
TVTX icon
100
Travere Therapeutics
TVTX
$5.89B
$2.24M 0.06%
90,748
-479,336
-84% -$12.4M
1 2 3
4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Perceptive Advisors held 127 positions worth $3.45B, up 7.9% from $3.19B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $255M in Q3 2022, closing 11 positions and reducing 24 holdings. Its most notable exit was Eli Lilly, an estimated $32.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Edwards Lifesciences worth $27.3M.

  • Perceptive Advisors's largest Q3 2022 buy was Edwards Lifesciences: 330,000 shares worth $27.3M.
  • Perceptive Advisors added most to Relmada Therapeutics in Q3 2022, an estimated $62.7M increase.
  • Perceptive Advisors's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $38.2M.
  • Perceptive Advisors fully exited Eli Lilly in Q3 2022, selling an estimated $32.4M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q3 2022.
  • Perceptive Advisors opened 16 new positions and closed 11 in Q3 2022.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.